Journal September 25, 2026 5 min read

What does the research say about AMPK activation?

AMPK is a heterotrimeric serine/threonine kinase that acts as a cellular energy sensor. This page summarises laboratory and clinical research on AMPK activation, including the compounds and models studied, and notes wher

peptides-pro Editorial

AMP-activated protein kinase (AMPK) is a heterotrimeric serine/threonine protein kinase consisting of a catalytic α-subunit and regulatory β- and γ-subunits [8]. It functions as a cellular energy sensor and is a target for pharmacological activators in research on endothelial dysfunction and metabolic regulation [8]. Common synonyms include 5' AMP-activated protein kinase and AMPK. The evidence block does not provide sequence, formula, or molecular weight identifiers.

The work centres on the AMPK signalling pathway and its downstream targets, including acetyl-CoA carboxylase (ACC) and interactions with AKT, NF-κB, JNK, and CREB/SIRT1 [2][4][10].

Research Studies

Astaxanthin and autophagy in granulosa cells from women with PMOS

A triple-blind, placebo-controlled pilot randomised trial evaluated whether astaxanthin (AST) modulates autophagy-related signalling in granulosa cells (GCs) from women with polyendocrine metabolic ovarian syndrome (PMOS), formerly referred to as polycystic ovary syndrome (PCOS) [1]. Fifty women with PMOS-related anovulatory infertility were enrolled between November 2023 and September 2024 and received AST (12 mg/day) or placebo [1]. The study assessed autophagy activation in GCs as a mechanism of AST action and related these molecular effects to ovarian response [1]. This is a clinical study in humans; the evidence block does not report AMPK-specific findings from this trial.

Oxidative eustress and AMPK/AKT activation in skeletal muscle cells and fibres

In C2C12 myoblasts and myotubes, AKT and AMPK phosphorylation were analysed after exposure to insulin and redox-modulating stimuli associated with oxidative eustress, including hydrogen peroxide, nitric oxide donors, and angiotensin II [2]. GLUT4 translocation was assessed by quantitative immunocytochemistry, and functional glucose uptake was measured [2]. The study reported that oxidative eustress is associated with AMPK and AKT activation, GLUT4 translocation, and glucose uptake in skeletal muscle cells and fibres [2]. This is an in vitro study using cell lines; findings may not extrapolate to whole organisms.

Salicylate binding partners and AMPK dependency in renal epithelial cells

In the context of autosomal dominant polycystic kidney disease (ADPKD), a targeted analysis of salicylate binding partners in renal epithelial cells revealed major AMPK dependency [3]. Previous work showed that activation of AMPK with salsalate ameliorates disease progression in vivo to a similar extent as tolvaptan, by affecting metabolic reprogramming, cell proliferation, and inflammation [3]. The current study aimed to clarify to which extent these effects depend on AMPK [3]. This is an in vitro study in renal epithelial cells; the evidence block does not provide in vivo data from this specific analysis.

AMPK and macrophage crosstalk in diabetes

A review investigated the bidirectional interaction between AMPK signalling and macrophage function in diabetes mellitus, especially type 2 diabetes (T2DM) [4]. In diabetes, adipose tissue macrophages adopt a pro-inflammatory M1 phenotype, secreting cytokines including TNF-α, IL-6, and IL-1β that disrupt insulin signalling and cause metabolic dysfunction [4]. AMPK suppresses M1 responses by inhibiting NF-κB and JNK signalling, activating CREB/SIRT1 pathways, and promoting oxidative metabolism [4]. This is a review; the evidence block does not specify whether the underlying studies were in vitro, animal, or human.

Bitter melon compounds and AMPK activation in myotonic dystrophy type 1 skeletal muscle

Myotonic Dystrophy Type 1 (DM1) is characterised by repression of the AMPK pathway [5]. A screen of 26 bitter melon-derived compounds (BMCs) in C2C12 myotubes identified BMC-25 as a potent AMPK activator [5]. The study investigated the therapeutic potential of novel AMPK activators derived from Momordica charantia (bitter melon) and reported that a bitter melon natural compound ameliorates the DM1 skeletal muscle phenotype in a sex-specific manner [5]. This is an in vitro study in C2C12 myotubes; the evidence block does not report human data.

TMZ plus 6-MP in recurrent glioblastoma

A clinical trial (NCT06279767) is evaluating the efficacy and safety of temozolomide (TMZ) plus 6-mercaptopurine (6-MP) in patients with recurrent glioblastoma [6]. Glioblastoma is the most prevalent malignant tumour in the central nervous system, with a median survival period of less than 14 months for high-grade cases [6]. Standard treatment involves surgical resection combined with postoperative radiotherapy and chemotherapy, with temozolomide playing a pivotal role [6]. This trial does not directly investigate AMPK activation; it is included as a clinical context for ongoing research.

Hepassocin and AMPK activation in liver senescence and regeneration

Hepassocin (HPS), a hepatokine with known hepatoprotective functions, was reported to prevent age-related liver senescence and facilitate liver regeneration by activating AMPK [7]. This is a reference-only item; the evidence block does not provide further details on the model or methods.

Pan-AMPK activator MK-8722 in human endothelial cells

The pan-AMPK activator MK-8722 was reported to outperform the AMPK activators SC4 and A-769662 in human endothelial cells [8]. AMPK regulates endothelial homeostasis and has emerged as a target for pharmacological activators in the treatment of endothelial dysfunction [8]. This is an in vitro study in human endothelial cells; the evidence block does not provide in vivo data.

Palmitic acid and AMPK suppression in airway epithelial cells

Obesity-related palmitic acid was reported to exacerbate IL-13-induced mucus phenotype in 16HBE airway epithelial cells via AMPK suppression [9]. Mucus hypersecretion and obesity are prevalent comorbidities that independently worsen childhood asthma outcomes [9]. This is an in vitro study in 16HBE cells; the evidence block does not report human data.

Exercise preconditioning and AMPK-ACC signalling in myocardial ischemia/reperfusion

In C57BL/6J mice, six weeks of treadmill exercise preconditioning (EP) before myocardial ischemia/reperfusion (I/R) was studied to determine whether it protects against I/R-induced ferroptosis and the underlying mechanisms [10]. Exercise preconditioning activates AMPK-ACC signalling and attenuates myocardial ischemia/reperfusion-induced ferroptosis [10]. This is an animal study; findings may not extrapolate to humans.

If you are reading this for personal health reasons

The materials and compounds discussed on this page are sold for laboratory research only. We do not provide dosing or medical guidance, and nothing here is intended for human use. Anyone considering a compound for themselves should speak to a licensed clinician.